Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3′-UTR of dengue types 1,2,3, and 4, or antigenic chimeric dengue viruses 1,2,3, and 4

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO RE46641
SERIAL NO

13896388

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The invention relates to a dengue virus tetravalent vaccine containing a common 30 nucleotide deletion (Δ30) in the 3′-untranslated region of the genome of dengue virus serotypes 1, 2, 3, and 4, or antigenic chimeric dengue viruses of serotypes 1, 2, 3, and 4.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY DEPARTMENT OF HEALTH AND HUMAN SERVICES6011 EXECUTIVE BOULEVARD SUITE 325 MSC 7660 BETHESDA MD 20892

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Blaney, Joseph E Gettysburg, US 26 91
Falgout, Barry Rockville, US 7 84
Hanley, Kathryn A Las Cruces, US 12 57
Lai, Ching-Juh Bethesda, US 31 232
Markoff, Lewis Bethesda, US 9 105
Murphy, Brian R Bethesda, US 96 972
Whitehead, Stephen S Bethesda, US 52 355

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Jun 19, 2025
11.5 Year Payment $7400.00 $3700.00 $1850.00 Jun 19, 2029
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00